Teva Scores against Novartis, GlaxoSmithKline
Teva is free to resume sales of its generic famciclovir (Novartis’ Famvir), following the US Court of Appeals for the Federal Circuit’s denial of Novartis’ emergency motion for an injunction against Teva. Here’s Teva’s press release (9/28).
Teva may also market, in the US, its generic versions of GlaxoSmithKline's Avandia (rosiglitazone maleate), Avandamet (rosiglitazone maleate/metformin HCl), and Avandaryl (rosiglitazone maleate/glimepiride) oral tablets, come 2012. Teva (9/27)
And that timing is seemingly good. As reported by The Boston Globe (9/27), Lahey Clinic researchers concluded from their study of Actos and Avandia that while drugs from that class increase the relative risk of heart failure (a previously known risk factor) in people who have type 2 diabetes, they do not raise the risk of cardiovascular death. An earlier review (6/07), by Steven E. Nissen of the Cleveland Clinic, found a significant increase in the risk of heart attack for people taking Avandia and a borderline-significant risk of cardiovascular death. The lead investigator for the Lahey Clinic study said the data his group examined were more robust than the results analyzed by Nissen.